Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinicopathological and molecular characterization of inflammatory breast cancer, the prospective INFLAME registry study.
van Geel JJL, Jongbloed EM, Moustaquim J, van der Schoor G, van Leeuwen-Stok AE, Smid M, van Deurzen CHM, Wilting SM, Wesseling J, Sonke GS, Martens JWM, Schröder CP. van Geel JJL, et al. Among authors: van leeuwen stok ae. NPJ Breast Cancer. 2025 May 29;11(1):48. doi: 10.1038/s41523-025-00764-5. NPJ Breast Cancer. 2025. PMID: 40442132 Free PMC article.
Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ - The LORD study.
Elshof LE, Tryfonidis K, Slaets L, van Leeuwen-Stok AE, Skinner VP, Dif N, Pijnappel RM, Bijker N, Rutgers EJ, Wesseling J. Elshof LE, et al. Eur J Cancer. 2015 Aug;51(12):1497-510. doi: 10.1016/j.ejca.2015.05.008. Epub 2015 May 26. Eur J Cancer. 2015. PMID: 26025767 Free article. Clinical Trial.
Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04).
van Rossum AGJ, Kok M, van Werkhoven E, Opdam M, Mandjes IAM, van Leeuwen-Stok AE, van Tinteren H, Imholz ALT, Portielje JEA, Bos MMEM, van Bochove A, Wesseling J, Rutgers EJ, Linn SC, Oosterkamp HM; MATADOR Trialists' Group. van Rossum AGJ, et al. Eur J Cancer. 2018 Oct;102:40-48. doi: 10.1016/j.ejca.2018.07.013. Eur J Cancer. 2018. PMID: 30125761 Free article. Clinical Trial.
Elastosis in ERα-positive male breast cancer.
Vermeulen MA, van Deurzen CHM, van Leeuwen-Stok AE, van Diest PJ. Vermeulen MA, et al. Virchows Arch. 2021 Feb;478(2):257-263. doi: 10.1007/s00428-020-02920-7. Epub 2020 Sep 15. Virchows Arch. 2021. PMID: 32929565 Free PMC article.
Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study.
Eijkelboom AH, de Munck L, Vrancken Peeters MTFD, Broeders MJM, Strobbe LJA, Bos MEMM, Schmidt MK, Guerrero Paez C, Smidt ML, Bessems M, Verloop J, Linn S, Lobbes MBI, Honkoop AH, van den Bongard DHJG, Westenend PJ, Wesseling J, Menke-van der Houven van Oordt CW, Tjan-Heijnen VCG, Siesling S; NABON COVID-19 Consortium and the COVID and Cancer-NL Consortium. Eijkelboom AH, et al. J Hematol Oncol. 2021 Apr 17;14(1):64. doi: 10.1186/s13045-021-01073-7. J Hematol Oncol. 2021. PMID: 33865430 Free PMC article.
Differential Survival and Therapy Benefit of Patients with Breast Cancer Are Characterized by Distinct Epithelial and Immune Cell Microenvironments.
Kester L, Seinstra D, van Rossum AGJ, Vennin C, Hoogstraat M, van der Velden D, Opdam M, van Werkhoven E, Hahn K, Nederlof I, Lips EH, Mandjes IAM, van Leeuwen-Stok AE, Canisius S, van Tinteren H, Imholz ALT, Portielje JEA, Bos MEMM, Bakker SD, Rutgers EJ, Horlings HM, Wesseling J, Voest EE, Wessels LFA, Kok M, Oosterkamp HM, van Oudenaarden A, Linn SC, van Rheenen J. Kester L, et al. Clin Cancer Res. 2022 Mar 1;28(5):960-971. doi: 10.1158/1078-0432.CCR-21-1442. Clin Cancer Res. 2022. PMID: 34965952 Free PMC article.
Tumor-infiltrating lymphocytes in HER2-positive breast cancer treated with neoadjuvant chemotherapy and dual HER2-blockade.
Liefaard MC, van der Voort A, van Seijen M, Thijssen B, Sanders J, Vonk S, Mittempergher L, Bhaskaran R, de Munck L, van Leeuwen-Stok AE, Salgado R, Horlings HM, Lips EH, Sonke GS. Liefaard MC, et al. Among authors: van leeuwen stok ae. NPJ Breast Cancer. 2024 Apr 18;10(1):29. doi: 10.1038/s41523-024-00636-4. NPJ Breast Cancer. 2024. PMID: 38637568 Free PMC article.
Predictive gene expression profile for adjuvant taxane benefit in breast cancer in the MATADOR trial.
Opdam M, van Rossum AGJ, Hoogstraat M, Bounova G, Horlings HM, van Werkhoven E, Mandjes IAM, van Leeuwen-Stok AE, Canisius S, van Tinteren H, Imholz ALT, Portielje JEA, Bos MEMM, Bakker S, Wesseling J, Kester L, van Rheenen J, Rutgers EJ, de Menezes RX, Wessels LFA, Kok M, Oosterkamp HM, Linn SC; MATADOR trialists’ group for the Dutch Breast Cancer Research Group (BOOG). Opdam M, et al. Among authors: van leeuwen stok ae. iScience. 2024 Jun 29;27(8):110425. doi: 10.1016/j.isci.2024.110425. eCollection 2024 Aug 16. iScience. 2024. PMID: 39206149 Free PMC article.
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer.
Sonke GS, van Ommen-Nijhof A, Wortelboer N, van der Noort V, Swinkels ACP, Blommestein HM, Guerrero Paez C, Mol L, Beeker A, Beelen K, Hamming LC, Heijns JB, Honkoop AH, de Jong PC, van Rossum-Schornagel QC, van Schaik-van de Mheen C, Tol J, Tromp-van Driel CS, Vrijaldenhoven S, van Leeuwen-Stok AE, Konings IR, Jager A; SONIA Study Consortium. Sonke GS, et al. Among authors: van leeuwen stok ae. Nature. 2024 Dec;636(8042):474-480. doi: 10.1038/s41586-024-08035-2. Epub 2024 Nov 27. Nature. 2024. PMID: 39604725 Clinical Trial.
Implementation of ultra-hypofractionated radiotherapy for breast cancer in the Netherlands in 2020-2023, using registry data and questionnaires.
Eijkelboom AH, van Beek EJA, Stam MR, Westhoff P, van Maaren MC, Sattler MGA, Bantema-Joppe EJ, Verheij M, van den Bongard DHJG, Siesling S; NABON-COVID-19 Consortium and the COVID and Cancer-NL Consortium. Eijkelboom AH, et al. Radiat Oncol. 2025 Jun 12;20(1):99. doi: 10.1186/s13014-025-02669-w. Radiat Oncol. 2025. PMID: 40506770 Free PMC article.
29 results